Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Carola Boccomini,Barbara Botto,Andrea Evangelista,Vittorio Ruggero Zilioli,Antonella Anastasia,Federica Cavallo,Francesco Merli,Manuela Zanni, Monica Tani,Annalisa Chiarenza,Anna Marina Liberati, Annarita Conconi,Paolo Corradini,Alessia Bari,Giorgia Annechini,Gianluca Gaidano,Michele Spina,Roberto Sartori,Claudia Castellino,Benedetta Puccini

Blood（2023）

引用 0|浏览2

暂无评分

摘要

Background: Elderly patients with relapsed/refractory (R/R) FL have limited treatment options. Lenalidomide has direct tumoricidal and antiangiogenetic actions on tumor cells and is able to modulate tumor-cell microenvironment. Lenalidomide combined with Rituximab (R 2) in induction has shown a good clinical activity with low toxicity in both untreated and R/R FL patients. R 2 as maintenance treatment is less studied.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要